University of Nijmegen (1655–80)

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Retrieved on: 
Friday, July 1, 2022
Board of directors, Patient, Research, GLOBE, BMS, COVID-19, Company, Industry, Food, Doctor of Philosophy, Drug development, Regulation of tobacco by the U.S. Food and Drug Administration, D Grubu, FDA, Hoffmann-La Roche, Omicron, Pharmaceutical Research and Manufacturers of America, Therapy, BS, University of Nijmegen (1655–80), Safety, IPO, CNTA, Pharmacometrics, McKinsey & Company, Biochemistry, Novartis, Senior, Clinical pharmacology, Hoffmann, Bristol Myers Squibb, Nasdaq, Board, Pharmacology, R, Senior advisor, U.S. Securities and Exchange Commission, Disease, Risk, University, Maintenance, PDUFA, MD, Program, Director, Pharmaceutical industry, Delta, Organon, Biology

I am very pleased to welcome Math to Centessas Board of Directors.

Key Points: 
  • I am very pleased to welcome Math to Centessas Board of Directors.
  • Im excited to join the Centessa Board at such a pivotal time for the Company, said Dr. Hukkelhoven.
  • Dr. Hukkelhoven received his BS and PhD with honors in Biology and Biochemistry from the University of Nijmegen, the Netherlands.
  • Dr. Hukkelhoven also serves on the Board of Directors of Compugen Ltd, and is a Senior Advisor to McKinsey and an R&D Strategy Advisor to LianBio.

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Retrieved on: 
Wednesday, June 1, 2022
Axiom Space, Company, Adenosine deaminase, Doctor of Philosophy, COVID-19, Supervisory board, University of Nijmegen (1655–80), U.S. Securities and Exchange Commission, Alnylam Pharmaceuticals, Intellectual property, Cancer, Forward-looking statement, CEO, MyTomorrows, Mass meeting, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, General counsel, Corporation, University, RNA, Security (finance), ProQR, Shareholder, Patient, Chief financial officer, Lawyer, GE Capital, AGM, Lists of diseases, Janssen Vaccines, Mutation, Leadership, Research, Annual report, Nasdaq, Therapy, GLOBE, ADAR, Risk, Corporate development, De Boer, Safety, Management, Pharmaceutical industry, Renewable energy

ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.

Key Points: 
  • ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.
  • Mr. Beukema is also nominated to join the Management Board, subject to approval by shareholders at the AGM.
  • Most recently, he has been General Counsel & Chief Corporate Development at Frame Cancer Therapeutics.
  • He is the scientific co-founder of ProQR and previously served as ProQRs Chief Innovation Officer from 2014 to 2022.

Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Retrieved on: 
Thursday, February 24, 2022
Failure, Security (finance), Company, Senior advisor, Compugen, Senior, Clinical pharmacology, R, Nasdaq, Private Securities Litigation Reform Act, Research, Bispecific monoclonal antibody, Board of directors, McKinsey & Company, Retirement, Risk, Board, Biochemistry, Novartis, TIGIT, Drug development, IO, Pharmacology, U.S. Securities and Exchange Commission, Bristol Myers Squibb, Terminology, Pharmaceutical Research and Manufacturers of America, University of Nijmegen (1655–80), TEL, AstraZeneca, D, Pharmacometrics, Atomic Energy Regulatory Board, Compugen (Israeli company), PDUFA, Forward-looking statement, Patient, Immunotherapy, University, Annual report, Industry, Science and technology in Asia, Acquisition, FDA, SEC, Pharmaceutical industry, Safety, PVRIG, Bayer, Biology

In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.

Key Points: 
  • In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.
  • "I am delighted to welcome Math to Compugen's Board," said Paul Sekhri, Chairman of the Board.
  • I would also like to thank Jean-Pierre who will end his tenure as a director on March 1, 2022, for his contributions to Compugen."
  • "I had the privileged opportunity to play a key role in the introduction of transformational immune-based therapies that are today changing patients' lives.